Navigation Links
Scarguard Labs, LLC Appoints Richard E. Pino as CFO
Date:1/14/2009

GREAT NECK, N.Y., Jan. 14 /PRNewswire/ -- Scarguard Labs, LLC, a closely held company specializing in the treatment of scars and other dermatological problems through the use of multi-technology drugs enhanced by a proprietary contact delivery system, announced it has appointed Richard E. Pino as Chief Financial Officer. He will be responsible for the Company's finance, accounting, and treasury functions and will report to Chief Executive Officer, Joel Studin, MD.

Prior to his appointment, Mr. Pino served as Chief Financial Officer / Chief Operating Officer for EcoSys Management LLC, a leader in enterprise project and operations financial management solutions. While there, Mr. Pino was responsible for overall operations: Finance, HR, Legal and Facilities. Previously, Mr. Pino was the Chief Financial Officer for The Relegence Corporation, which became a wholly-owned subsidiary of AOL, a TimeWarner Company during Pino's tenure.

From 2001 through 2005, Pino was the CFO for Frontline Communications International, Inc. where he was responsible for overall operations as well as overseeing outside accounting, tax and legal firms. Prior to 2001, Mr. Pino held various financial positions in of the following industries: Telecom, investment banking and media. He currently serves in a financial capacity on the boards of several non-profit organizations, including The Brooklyn Philharmonic and the Museum of Biblical Art.

Mr. Pino received his BA from St. Francis College in 1990 and his MBA from Adelphi University in 1993.

Speaking of Mr. Pino's appointment, Dr. Studin said, "We couldn't be happier that Richard agreed to join our Company. His experience covers all aspects of the finance, treasury and accounting roles, and includes strategic planning, mergers and acquisitions, all roles that he will fulfill while at Scarguard. He will be a key part of Scarguard's growth as a company."

About Scarguard Labs, LLC.

Scarguard Labs, LLC is a closely held pharmaceutical company specializing in dermatological medications employing an internationally patented delivery system designed to enhance drug effectiveness utilizing a multi-technology approach. Our flagship product, Scarguard, is the most frequently dispensed product for scars in plastic surgery offices since 2001. In addition, it can be found in most pharmacies, drug distributors and major grocery chains throughout the United States. We have multiple topical prescription and non-prescription drugs in the marketplace, or in varying stages of development. For more information, please visit our website at www.scarguard.com

    Company Contact:
    Richard E. Pino
    Chief Financial Officer /Investor Relations
    Scarguard Labs, LLC
    516-482-8050
    Richard@scarguard.com

    Investor Relations:
    John McNamara
    Cameron Associates
    (212) 245-8800 Ext. 205
    john@cameronassoc.com


'/>"/>
SOURCE Scarguard Labs, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Scarguard Labs, LLC Expands Distribution Reach Through Agreements With McKesson Drugs and Publix Supermarkets
2. Innovatech Labs, Assisting Companies in Adhering to Halogen-Free Manufacturing Standards Aimed at Protecting the Environment
3. ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
4. Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board
5. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
6. ev3 Inc. Appoints Shawn McCormick as New Sr. Vice President and Chief Financial Officer
7. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
8. Hillenbrand, Inc. Appoints Jan Santerre Vice President of Lean Business
9. eDiets.com(R) Appoints Kevin N. McGrath as President and CEO
10. Bon Secours Charity Health System Appoints Terence M. O'Brien as Chief Executive Officer
11. Bat Saliva-Based Stroke Drug Disappoints in Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection ... reprocessing cycle, both between patient procedures and before storage, is a requisite practice ... important to the prevention of disease transmission and nosocomial infection as cleaning and ...
(Date:8/16/2017)... ... 16, 2017 , ... Richard Strawn’s new book Surgical ... of a cancer diagnosis, surgery and recovery, the Psalms provided encouragement and hope, ... God shows love to those who are sick., Surgical Psalms contains 36 reflections ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and marketers of high-quality anti-aging skincare solutions, recently announced the launch of two ... are an affordable, yet effective alternative to expensive plastic surgery or in-patient cosmetic ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
Breaking Medicine Technology: